Baxter International (BAX) produces 60% of the IV fluid bags used in U.S. hospitals, operates the leading drug compounding business in the country, and makes the surgical hemostats and sealants used in a significant portion of U.S. operating rooms. The company generated $11.24 billion in revenue in 2025 and approximately $951 million in operating cash flow. The stock is down roughly 40% over the past twelve months and trades at approximately $18 per share, implying a forward earnings multiple below 10x.
The reason the stock is where it is comes down to three overlapping problems arriving simultaneously. Hurricane Helene in September 2024 flooded Baxter’s primary U.S. IV manufacturing facility in Marion, North Carolina, and the fluid conservation measures hospitals adopted in response turned out to be permanent. The Novum IQ large-volume infusion pump (Baxter’s next-generation flagship product), cleared by the FDA in April 2024, accumulated five separate Class I recalls within fourteen months, including two deaths and eighty-two serious injuries, and remains under a voluntary ship-and-installation hold that management expects to last through the entirety of 2026. And the 2021 acquisition of Hillrom for approximately $10.5 billion left the balance sheet with $9.5 billion in long-term debt and goodwill that has already been impaired by $910 million in two consecutive years, with $1.52 billion still on the books.
Against all of that, the underlying business generates real cash. Interest expense has declined by approximately $100 million per year from peak levels and is still falling. The 2026 debt maturity wall has been cleared entirely. The new CEO has cut the dividend to near zero, sold two major business units, and launched a cost reduction program. Whether those actions are sufficient, and whether they arrived early enough, is the central question for anyone looking at Baxter today.
What Baxter Does
Baxter is a medical products company that serves the acute care environment: hospitals, surgery centers, and critical care settings. It does not develop drugs in the pharmaceutical sense. It manufactures the consumables, devices, and services that hospitals consume continuously: IV bags, infusion pumps, drug compounding, surgical sealants, patient monitoring equipment, and smart hospital infrastructure.
The company has approximately 37,500 employees operating across more than 100 countries, with manufacturing in the U.S., Ireland, Singapore, India, and other international sites. Headquarters is in Deerfield, Illinois.
Baxter has been restructuring aggressively. In October 2023 it sold its BioPharma Solutions business (a contract drug manufacturing operation) for $4.25 billion. In January 2025 it sold the Kidney Care business, now operating as Vantive, to Carlyle Group for $3.8 billion. Combined, those two divestitures generated more than $8 billion in proceeds and eliminated more than $6.6 billion in net debt. The company that exists today is a smaller, more focused entity than Baxter was three years ago.
The Three Segments
Medical Products & Therapies: $5.3 billion, 47% of revenue
| Division | FY2025 Revenue | FY2025 Growth |
|---|---|---|
| Infusion Therapies & Technologies | $4.1B | flat |
| Advanced Surgery | $1.2B | +9% YoY |
| Total | $5.3B | +2% |
Infusion Therapies covers IV solutions, infusion pumps and sets, and parenteral nutrition. This is the company’s largest division by revenue and its structural moat: Baxter and ICU Medical together supply the overwhelming majority of U.S. IV fluid production, with Baxter’s Marion, North Carolina facility alone producing approximately 60% of national supply. Hospitals do not easily change IV solution suppliers; the logistics, contracts, and clinical protocols are deeply embedded. The infusion pump business is where Novum sits, currently under a ship-and-installation hold.
Advanced Surgery covers hemostatic agents, surgical sealants, and adhesion prevention products. It is the best-performing division in the segment, growing 9% for the full year, and is not facing any of the headwinds affecting the rest of MP&T.
Segment operating margin was 18.3% for the full year, the highest in the portfolio, contributing approximately 60% of total segment operating income despite representing 47% of revenue.
Healthcare Systems & Technologies: $3.1 billion, 27% of revenue
| Division | FY2025 Revenue | FY2025 Growth |
|---|---|---|
| Care & Connectivity Solutions | $1.9B | +5% YoY |
| Front Line Care | $1.2B | +2% YoY |
| Total | $3.1B | +4% |
Care & Connectivity Solutions covers smart hospital beds, nurse call systems, and surgical integration infrastructure, products acquired through the Hillrom acquisition. Front Line Care covers the Welch Allyn brand: vital signs monitors, spot-check devices, and respiratory diagnostics used in every clinical setting from the emergency department to the physician’s office.
Segment operating margin was 14.4% for the full year. Revenue grew; margins fell. The culprit is cost absorption: after the Kidney Care sale reduced the number of divisions sharing corporate overhead, HS&T now carries a materially larger allocation. This structural pressure persists until the cost base is right-sized. The segment also carries $1.52 billion in goodwill remaining after $910 million in impairments over the past two years, $485 million in 2025 and $425 million in 2024.
Pharmaceuticals: $2.5 billion, 22% of revenue
| Division | FY2025 Revenue | FY2025 Growth |
|---|---|---|
| Injectables & Anesthesia | $1.4B | -2% YoY |
| Drug Compounding | $1.1B | +10% YoY |
| Total | $2.5B | +3% |
Drug Compounding provides hospital pharmacy compounding services, custom sterile preparations delivered directly to hospitals. It is growing at double digits and generates demand independent of the broader device business. Injectables & Anesthesia faces ongoing pricing competition, declining 2% in 2025. Segment operating margin was 8.9% in 2025, down from 13.0% in 2024; the compression reflects product mix and the thin-margin manufacturing services Baxter now provides to the divested Vantive entity under a transitional manufacturing agreement.
The IV Solutions Moat and Its Permanent Reset
Producing sterile IV solutions at commercial scale is a technically demanding, capital-intensive, FDA-regulated manufacturing process. A new entrant would require years of facility construction, validation, and regulatory approval before delivering a single unit of supply to a hospital system. The North Carolina facility that Baxter operates took decades to build to its current output. The result is a market structure that does not change quickly: Baxter and ICU Medical dominate domestic production, and the hospitals that depend on them have no practical alternative on short notice.
Hurricane Helene made that dependency visible in September 2024. Floodwaters damaged the Marion facility, cutting national IV fluid supply sharply at a time when hospitals had no inventory buffer or domestic backup. The shortage lasted several months.
What happened next was not what Baxter expected. Hospitals responded by implementing fluid conservation protocols: oral hydration substitution for mild dehydration, IV push administration eliminating the bag entirely for certain medications, EHR-level friction requiring clinicians to confirm the need for a second bag before ordering, and elimination of the reflexive bag replacement when patients transferred between units. Studies across major health systems showed IV fluid consumption declining 40 to 55% during the acute shortage period.
The manufacturing facility has been repaired. IV fluid supply has been restored. The conservation protocols have not been reversed.
The academic foundation for what hospitals implemented is not new; a decade’s worth of literature suggests that IV fluids are routinely overused in settings where oral hydration would be clinically equivalent. The shortage did not create the evidence; it gave hospitals the urgency to act on it. EHR order sets have been updated, clinicians have been trained, and patient outcomes under the reduced protocols have been comparable. Unbuilding those protocols now that supply is available requires institutional will that is not materializing.
The acute 40 to 55% consumption drop moderated as supply was restored, but demand has not returned to pre-Helene levels. Management acknowledged on the Q4 2025 earnings call that the reduced IV demand represents the new baseline; the CFO characterized the sustained reduction as approximately 10 to 15% below pre-Helene levels. The Infusion Therapies division, at $4.1 billion Baxter’s single largest source of revenue, will operate off that reset demand curve for the foreseeable future.
The Novum IQ Recall
Baxter received FDA 510(k) clearance for the Novum IQ large-volume infusion pump in April 2024. The Novum was designed to replace the aging Spectrum platform and serve as the cornerstone of Baxter’s connected care vision, a pump that would integrate with smart beds, patient monitoring, and the hospital data layer. Within fourteen months of clearance, it had accumulated five separate Class I recalls.
| Date | Issue | Patient Events |
|---|---|---|
| April 2025 | Underinfusion from standby mode / compressed tubing | — |
| June 2025 | Updated instructions for use re: standby mode | — |
| July 2025 | Underinfusion when transitioning to flow rates more than double the prior rate; worst case: zero delivery | 79 serious injuries, 2 deaths |
| August 2025 | Blank run screen and false motor system errors | 3 serious injuries |
| October 2025 | Syringe pump underdosing; software miscalculates volume after detecting a blockage | — |
The July recall is the one that matters most clinically. The pump can fail to deliver medication at all when transitioning from a lower to a higher infusion rate exceeding a 2x magnitude change. The amount of underinfusion varies based on the starting rate, how long the pump ran at that rate, and the size of the rate change. This is not an edge case in oncology or critical care, where infusion rates are adjusted frequently and precisely.
All five issues trace to software, not hardware. That is structurally positive: a firmware overhaul and validation process can, in principle, resolve all of them without replacing the physical device. Baxter told hospital customers to expect a software upgrade and provided interim mitigation instructions, including directing facilities to use alternative pumps for high-risk medications and critically ill patients.
But the bugs are distinct, and each requires its own fix, validation study, and FDA review. Delivering a comprehensive software update that addresses all five issues simultaneously, and convincing the FDA to clear it, is not a fast process. The FDA page for the October 2025 syringe pump recall was last updated in January 2026, meaning new information is still flowing as of this writing. Management’s base-case planning assumption is that the ship-and-installation hold remains in place for the full year 2026. They may be right.
The strategic damage is harder to quantify than the $105 million in charges booked to date. The infusion pump market does not work like a consumer market. Hospitals standardize on a single pump platform across the facility; drug libraries, dosing protocols, and staff training are all specific to the platform in use. A decision to standardize on BD Alaris or an ICU Medical pump is a seven-to-ten-year commitment. Every month the Novum hold extends, hospital systems that would otherwise have been Novum customers are signing those long-term commitments with competitors. Baxter can win those accounts back eventually, but at enormous sales cost and over years, not quarters.
The Hillrom Problem
In late 2021, Baxter acquired Hillrom Holdings for approximately $10.5 billion. To understand why the acquisition was appealing and why it has been difficult, it helps to know what Hillrom actually was.
Hillrom was founded in 1929, originally as a furniture company that gradually pivoted into hospital furnishings. Over nearly a century it became the dominant manufacturer of the powered hospital bed, the electronically adjustable, sensor-equipped bed that is in virtually every U.S. acute care facility. Hill-Rom beds are so entrenched in U.S. hospitals that “Hill-Rom” is used generically by clinical staff the way “Kleenex” is used for tissues. That installed base comes with long-term service contracts, software subscriptions for the nurse call and patient monitoring integrations built into the bed platform, and meaningful switching costs; hospitals don’t swap out their entire bed fleet casually.
In 2015, Hillrom acquired Welch Allyn for approximately $2 billion. Welch Allyn is the company behind the diagnostic instruments found in virtually every exam room and emergency bay in the country: the handheld devices used to examine eyes and ears, check blood pressure, and monitor vital signs. Clinicians encounter Welch Allyn devices starting in medical school; the brand has deep familiarity and trust embedded across the entire clinical workforce.
Together, those two acquisitions gave Hillrom an unusual position: equipment at the patient’s bedside (the Hill-Rom bed) and equipment at the point of care across the facility (Welch Allyn monitoring and diagnostics), connected through a software and communications layer. That is exactly what Baxter was buying. Today, the entire Hillrom business lives inside the Healthcare Systems & Technologies segment, split into two divisions. Care & Connectivity Solutions ($1.9 billion) is the Hill-Rom bed business: smart beds, nurse call systems, and surgical integration infrastructure. Front Line Care ($1.2 billion) is the Welch Allyn business: vital signs monitors, spot-check devices, and respiratory diagnostics. No part of that segment existed inside Baxter before 2021.
The execution has been expensive.
| Year | Goodwill Impairment | Remaining Goodwill |
|---|---|---|
| 2024 | $425M | ~$2.0B |
| 2025 | $485M | $1.52B |
| Two-year total | $910M | — |
In addition to the goodwill impairments, Baxter wrote down the Welch Allyn trade name by $290 million. The combined impairment charges over two years total more than $1.2 billion. The most mechanically significant driver is rising interest rates: higher discount rates compress the present value of future cash flows in a DCF-based impairment test, and the Hillrom assets were acquired at prices that assumed a lower rate environment. But the magnitude of the write-downs over two consecutive years also reflects revenue and margin performance that has come in below acquisition-era projections.
The stated thesis for the acquisition was a connected care platform: beds, pumps, monitoring devices, and data analytics integrated into a single hospital operating system. Baxter would sell hospitals a connected ecosystem rather than individual products. That vision is still the stated strategy. In September 2025, Baxter launched the Welch Allyn Connex 360 Vital Signs Monitor, described as the foundation for future connected monitoring integration. Across the Q3 and Q4 2025 earnings calls, management characterized Front Line Care as an investment case rather than a divestiture candidate. The logic is that selling Welch Allyn would break the monitoring layer out of the connected care architecture, leaving Baxter with beds and pumps but no patient vitals data flowing into the integrated ecosystem.
Whether the connected care thesis is the right strategic framework or a justification for not selling an impaired asset at an unfavorable price is a question the financial statements cannot fully answer. What they can answer is this: the segment generates real cash, Baxter paid $10.5 billion for Hillrom in 2021, has already written down $910 million of that in two consecutive impairment tests, and still carries $1.52 billion in HS&T goodwill, in an interest rate environment that has not materially improved since the last write-down. A third consecutive impairment would be non-cash and wouldn’t change the underlying business, but it would make the connected care thesis difficult to defend publicly for a third straight year, and hand the rating agencies a concrete data point at exactly the wrong moment in the deleveraging timeline. The most elegant resolution may not be an outright sale; selling now would mean realizing the overpayment at the worst possible price. A partial spin-off would let the public market establish an independent valuation, potentially demonstrating that the segment is worth more than the impairment tests imply, while allowing Baxter to retain the majority stake and use the proceeds to accelerate deleveraging. Management has not signaled this publicly, but the logic is hard to argue with if the annual write-downs continue.
Financial Profile
Income Statement: FY2025
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $11.24B | $10.57B |
| Adjusted Segment Operating Income | $1.63B | $1.57B |
| GAAP Net Loss | ($957M) | ($641M) |
| Operating Cash Flow | $951M | $786M |
| Capital Expenditures | $513M | $478M |
| Free Cash Flow | ~$438M | ~$308M |
| Net Interest Expense | $238M | $336M |
The GAAP net loss is not the operational picture. It reflects $910 million in goodwill impairments, $105 million in Novum recall charges, restructuring charges of $178 million, and amortization of Hillrom intangibles. The underlying free cash flow of approximately $438 million is the number that matters for debt service.
Balance Sheet: December 31, 2025
| Item | 2025 | 2024 |
|---|---|---|
| Cash | $1.97B | $1.76B |
| Total Assets | $20.1B | $25.8B |
| Long-term Debt | $9.47B | $10.37B |
| Total Equity | $6.1B | $7.0B |
| Goodwill | $4.93B | $5.28B |
| Intangibles, net | $4.37B | $5.22B |
| Pension underfunding | $471M | — |
Total assets declined $5.7 billion year over year because the Kidney Care segment (approximately $5 billion in assets) was removed when the sale to Carlyle closed in January 2025.
Debt Maturity Schedule
| Year | Maturity |
|---|---|
| 2026 | $0 |
| 2027 | $841M |
| 2028 | $1.34B |
| 2029 | $1.18B |
| 2030 | $1.20B |
| 2031+ | $4.93B |
In December 2025, Baxter issued $2 billion in new notes ($300 million at 4.45%, $700 million at 4.90%, $1.0 billion at 5.65%) and used the proceeds to eliminate all 2026 maturities. There is no refinancing cliff in 2026. The new notes carry no maintenance financial covenants: no leverage ratio test, no interest coverage requirement, no EBITDA floor. The covenants are incurrence-based, meaning a technical default requires Baxter to take an affirmative action that violates a covenant, not merely to report a weak quarter. The $2.2 billion revolving credit facility, undrawn, matures 2030 and provides a backstop; unlike the notes, the revolver does carry a maximum net leverage ratio covenant, which Baxter amended in November 2025 to obtain temporary relief through September 2026.
Interest Expense Trajectory
| Period | Net Interest Expense |
|---|---|
| Q3 2024 (annualized) | ~$348M |
| Q3 2025 (annualized) | ~$232M |
| Reduction | ~$116M/year |
This is the single most concrete financial benefit of the BioPharma Solutions and Vantive divestitures already flowing through the income statement.
The IRS Situation
Baxter carries $329 million in gross unrecognized tax benefits as of December 31, 2025, up from $96 million a year earlier. The $233 million increase is attributable to transfer pricing positions covering the company’s Costa Rica and Puerto Rico operations for tax years 2019 through 2025. No Notice of Proposed Adjustment has been received. Management describes the positions as well-documented. The reserve-building tells a different story about internal confidence. If the IRS pursues these positions and prevails, a cash payment in the range of $280 to $329 million would be material to a company generating $438 million in free cash flow.
The effective tax rate for 2025 was negative 78%: Baxter paid $395 million in taxes on a $505 million pre-tax loss. The Q3 2025 quarter alone contributed $213 million in tax expense from IRS reserve additions, pushing the Q3 effective tax rate to 142% on a profitable quarter. The Switzerland tax incentive that provided more than $57 million in annual benefit expired at the end of 2024 and is not being replaced.
Credit Rating
| Agency | Rating | Outlook |
|---|---|---|
| Moody’s | Baa3 | Stable |
| S&P | BBB- | Stable |
Both agencies downgraded Baxter in Q4 2025 but simultaneously revised their outlooks to Stable, reflecting the December refinancing that eliminated the 2026 maturity wall and management’s credible deleveraging plan. Baxter sits one notch above junk at both agencies. A further downgrade at Moody’s would move Baxter to speculative grade, triggering mandatory selling from investment-grade bond funds, higher refinancing costs across the full $9.5 billion debt stack, and potentially accelerating the very balance sheet deterioration the downgrade was signaling. Management’s stated target of 3.0x net leverage by the end of 2026 is the number both agencies are watching. The Stable outlooks provide runway, but they are not permanent: another year of missed execution would reopen the question.
Management and Capital Allocation
Andrew Hider became CEO in July 2025. He is less than a year into the role and has not yet had a full business cycle in the seat. The decisions made since his appointment include cutting the quarterly dividend from its prior level to $0.01 per share ($0.04 annualized), refinancing the 2026 debt maturities, launching a cost reduction program, and bringing in board members with relevant financial restructuring backgrounds.
The dividend cut is worth examining specifically. Baxter had paid a dividend continuously for decades. At the prior rate, dividends consumed approximately $260 million per year. Cutting to $0.04 annually frees that capital entirely for debt reduction. The cut was not made from a position of strength; the balance sheet left no real alternative. But the history of companies in analogous situations, highly leveraged with a credible deleveraging thesis and a dividend that cannot be sustained, is largely a history of management teams that delayed the cut, preserved appearances at the cost of optionality, and ultimately cut from a weaker position. The decision to cut early and completely is the right capital allocation choice, and it required willingness to accept the negative market reaction that accompanied it.
The divestiture track record since 2023 follows the same pattern. Kidney Care was a meaningful historic business; the dialysis product line had been part of Baxter since the 1950s. BioPharma Solutions had been built over many years. Selling both, at reasonable prices, ahead of further balance sheet stress, reflects a management team (across two CEOs) that prioritized financial integrity over asset attachment.
The test of the current team is whether they can execute the operating model transformation that the divested businesses required. The $178 million in restructuring charges in 2025, the “Baxter Growth and Performance System” launched in October 2025, and the stated target of 100 basis points of annual operating margin improvement are the right stated priorities. Whether they produce the results that the credit clock requires is what 2026 will answer.
Valuation
Baxter trades at approximately $18 per share on 518 million shares, implying a market capitalization of approximately $9.3 billion. Net debt is approximately $7.5 billion, giving an enterprise value of approximately $16.8 billion.
2026 Financial Inputs (management guidance)
| Input | Value |
|---|---|
| Revenue | ~$11.3B (flat to +1%) |
| Adjusted operating margin | 13–14% |
| Adjusted operating income | $1.47–1.58B |
| D&A | ~$650M |
| Forward EBITDA | ~$2.2B |
| Adjusted EPS (guidance midpoint) | $1.95 |
| Capex | ~$480M |
| Normalized FCF | ~$700–800M |
| Forward P/E at $18 | ~9.2x |
Method 1: DCF (Five-Year)
WACC derivation: risk-free rate 4.5%, equity risk premium 5.5%, levered beta 1.2, yielding a cost of equity of 11.1%; after-tax cost of debt approximately 4.5%; capital weights 47% equity / 53% debt; blended WACC approximately 7.6%, adjusted to 9.5% to reflect execution risk.
FCF projections reflect: 2026 at management guidance levels, 2027 step-up when the Vantive MSA expires and gross margins begin recovering toward the high 30s, 2028-2030 steady improvement as interest expense continues declining and restructuring costs roll off. The bull case adds meaningful pump revenue from a Novum hold resolution in 2027.
| Year | Bear | Base | Bull |
|---|---|---|---|
| 2026 | $600M | $750M | $900M |
| 2027 | $750M | $1,000M | $1,150M |
| 2028 | $850M | $1,200M | $1,350M |
| 2029 | $900M | $1,350M | $1,500M |
| 2030 | $925M | $1,400M | $1,600M |
| Terminal growth | 2.0% | 2.5% | 3.0% |
| Terminal value | $12.5B | $20.5B | $30.0B |
| PV of FCFs | $3.1B | $4.3B | $5.0B |
| PV of terminal value | $7.9B | $13.0B | $19.9B |
| Total EV | $11.0B | $17.3B | $24.9B |
| Less net debt | $8.0B | $7.5B | $7.0B |
| Equity value | $3.0B | $9.8B | $17.9B |
| Per share | $5.79 | $18.92 | $34.56 |
Method 2: EV/EBITDA
The relevant range for Baxter is 8x to 11x on forward EBITDA of $2.2 billion. An 8x multiple reflects the junk downgrade risk, IRS exposure, and Novum hold extending. An 11x multiple assumes Novum resolution, credit stabilization, and the Vantive MSA rolling off. The company’s structural moat in IV solutions (60% of national supply, hospital switching costs, no new domestic competitors possible in the near term) argues against a multiple below 8x absent a genuine credit crisis.
| Multiple | EV | Less net debt | Equity | Per share |
|---|---|---|---|---|
| 8x | $17.6B | $8.0B | $9.6B | $18.53 |
| 9.5x | $20.9B | $7.5B | $13.4B | $25.87 |
| 11x | $24.2B | $7.0B | $17.2B | $33.20 |
Method 3: Sum of the Parts
The three segments have different business characteristics and deserve different multiples.
MP&T contains a near-monopoly essential consumables business (IV solutions) alongside a fast-growing surgical products unit. A 12x EBITDA multiple is justified by the switching costs, regulatory barriers, and essential product nature. HS&T carries two consecutive goodwill impairments and an uncertain strategic direction; 7x reflects that, with a further 10% haircut for residual impairment risk. Pharma at 8.5x reflects the Drug Compounding growth offset by declining Injectables margins.
| Segment | EBITDA | Multiple | Segment EV |
|---|---|---|---|
| MP&T | ~$1.17B | 12x | $14.0B |
| HS&T | ~$796M | 7x (−10% haircut) | $5.0B |
| Pharmaceuticals | ~$372M | 8.5x | $3.2B |
| Corporate overhead | ($280M) | 7x | ($2.0B) |
| Conglomerate discount | — | 10% | ($2.0B) |
| Total EV | $18.2B | ||
| Less net debt | $7.5B | ||
| Per share | $20.66 |
Method 4: Normalized Earnings Power
When the Vantive MSA expires (estimated early 2027) and gross margins recover toward the high 30s, normalized EPS is approximately $2.70 on $11.8 billion in revenue at a 16% adjusted operating margin, $170 million in net interest, and a 19% tax rate.
| Multiple | Per share |
|---|---|
| 8x (value trap pricing) | $21.60 |
| 10x | $27.00 |
| 12x | $32.40 |
Triangulation
| Method | Bear | Base | Bull |
|---|---|---|---|
| DCF | $6 | $19 | $35 |
| EV/EBITDA | $19 | $26 | $33 |
| Sum of Parts | $15 | $21 | $28 |
| Normalized P/E (2027E) | $22 | $28 | $32 |
| Average | ~$16 | ~$24 | ~$32 |
At approximately $18 per share, the stock is roughly at fair value in the bear case and meaningfully undervalued in the base and bull cases. The DCF bear case of $6 requires the IRS reserve crystallizing into a cash payment, a junk credit downgrade, the Novum hold extending into 2027, and the IV conservation reset proving deeper than currently modeled, all simultaneously. That scenario is a tail risk, not the base case.
The most important single input to the model is whether Baxter hits its 3.0x net leverage target by year-end 2026. If it does, the credit rating risk largely evaporates and the stock should rerate toward the base case of approximately $24. If it misses, due to another negative earnings event, IRS cash outlay, or further operational deterioration, the bear case becomes the working assumption.
What to Watch
| Catalyst | Why It Matters | Timeline |
|---|---|---|
| Q1 2026 earnings | Management guided to Q1 as the most challenging quarter of 2026, with improvement back-half weighted; a miss here reopens the credit downgrade scenario | April 30, 2026 |
| Net leverage vs. 3.0x target | The single number both rating agencies are watching; missing it at year-end 2026 likely triggers a junk downgrade | EOY 2026 |
| Novum IQ software update and FDA pathway | A comprehensive firmware fix and FDA clearance restarts pump revenue and validates the connected care thesis; continued silence on timeline extends the strategic damage | Ongoing; hold expected through 2026 |
| IRS transfer pricing resolution | $300M+ in reserves and growing; a Notice of Proposed Adjustment would begin the formal dispute process and could crystallize into a material cash outflow | Unknown; no NOPA received yet |
| Vantive MSA expiration | The majority of transitional manufacturing agreements fall off in early 2027; this is the primary trigger for gross margin recovery from current ~33% toward historical levels | Early 2027 |
| HS&T goodwill impairment test | $1.52B in goodwill remaining after $910M in two-year impairments; any further discount rate increase or revenue shortfall could trigger a third consecutive impairment | Annual test, disclosed in 10-K |
| Front Line Care strategic decision | Management is investing in the Connex 360 and maintaining the connected care thesis; any signal of a strategic review or divestiture process would reprice the segment significantly | Ongoing |
| DOJ CID on IV containers | December 2025 document request on IV flexible container production and False Claims Act compliance; early stage, unknown scope, potentially material | Monitor Legal Proceedings section of each quarterly filing; absence from future disclosures signals resolution |
| Tariff impact vs. guidance | 2026 guidance embeds $130–140M in tariff headwinds; any escalation of U.S. trade policy affecting medical devices and pharmaceuticals could move that number materially | Each earnings release |
| Q2 2026 earnings | First quarter where management expects improvement; the first observable step in the back-half-weighted recovery narrative | July/August 2026 |
Baxter International 10-K (February 12, 2026)
Baxter International 10-Q Q3 2025 (November 4, 2025)
Baxter International 8-K: Q4 2025 Earnings (February 12, 2026)
Baxter International 8-K: December 2025 Refinancing (December 4, 2025)
Research and analysis conducted with AI assistance using SEC EDGAR filings as primary sources.